Elicio Therapeutics held its 2026 Annual Meeting of Stockholders on November 12, 2026. Shareholders elected three Class III directors (Julian Adams, Jay R. Venkatesan, and Carol Ashe) to three-year terms and ratified Baker Tilly US, LLP as the company's independent auditor for the fiscal year ending December 31, 2026.
Elicio Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its camupepimut clinical program. The company highlighted Phase 2 AMPLIFY-7P data in pancreatic cancer showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, which will inform its Phase 3 strategy.
“We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late-stage development and refine our Phase 3 strategy in adjuvant PDAC.”
Robert Connelly, President and Chief Executive Officer
“The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.”
Robert Connelly, President and Chief Executive Officer
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing camupepimut (ELI-002 7P) for adjuvant PDAC and other mKRAS-driven cancers. As of November 3, 2026, the company had 28,307,225 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.